Immunotherapy and circulating tumor DNA in HPV-positive oropharyngeal cancer: a systematic review and exploratory meta-analysis of survival and surveillance outcomes
Cancer Treatment and Research Communications · 2026 · 49 · 101477
DOI: 10.1016/j.ctarc.2026.101477 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Mohammad Mahmoud Aouf und 4 weiteren Autor:innen. Beteiligte Einrichtung: Otorhinolaryngology Department, Faculty of Medicine, Kafr El-Sheikh University, Kafr El-Sheikh, Egypt; Otorhinolaryngology Department, Semmelweis Uni…. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Human papillomavirus-positive oropharyngeal squamous cell carcinoma is biologically distinct, yet the effect of immune checkpoint inhibition and the performance of circulating tumor DNA (ctDNA) as a biomarker remain undefined. METHODS: We searched databases through October 2025 for prospective studies of adults with HPV-positive OPSCC that reported survival after immune checkpoint inhibition or plasma ctDNA/ctHPVDNA as a prognostic or surveillance biomarker. Two reviewers performed selection, extraction, ROBINS-I, and GRADE. Hazard ratios were pooled by inverse variance (common-effect; DerSimonian-Laird sensitivity), the two streams separately. RESULTS: Six prospective studies (n = 295 HPV-positive patients) were included; none provided an internal immunotherapy-versus-no-immunotherapy contrast. ctDNA was consistently prognostic: across the three with a within-cohort ctDNA-stratified contrast (k = 3, n = 169), pooled hazard ratios were 0.67 (95% CI 0.57-0.80) for progression-free survival and 0.71 (95% CI 0.60-0.85) for overall survival. Whole-evidence-based estimates were 0.70 (95% CI 0.59-0.83) and 0.74 (95% CI 0.63-0.88), with substantial heterogeneity (I² = 63.6% and 67.9%), and are carried by the ctDNA contrasts, holding 89% (PFS) and 81% (OS) of pooled weight. The three studies contributing immunotherapy-associated estimates (k = 3, n = 126) showed no benefit (PFS HR, 0.96; 95% CI, 0.58-1.59; OS HR, 0.90; 95% CI, 0.62-1.32). CONCLUSIONS: Plasma ctDNA/ctHPVDNA performed consistently as a prognostic and surveillance biomarker, with early clearance predicting better survival within treated cohorts. The evidence for prospective immunotherapy is too sparse and imprecise to demonstrate a survival benefit, and the favorable pooled signal should not be attributed to immunotherapy. Randomized, biomarker-stratified trials are required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Otorhinolaryngology Department, Faculty of Medicine, Kafr El-Sheikh University, Kafr El-Sheikh, Egypt; Otorhinolaryngology Department, Semmelweis University, Budapest, Hungary. Electronic address: mohammad.aouf@med.kfs.…
- Otorhinolaryngology Department, Semmelweis University, Budapest, Hungary; Department of voice, speech, and swallowing therapy, Semmelweis University, Budapest, Hungary.
- Otorhinolaryngology Department, Faculty of Medicine, Kafr El-Sheikh University, Kafr El-Sheikh, Egypt.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Otorhinolaryngology Department, Semmelweis University, Budapest, Hungary.
Zitieren
APA
Aouf, M. M., Tamás, L., El-Shirbeny, H. A., Abdel-Maboud, M., & Dános, K. (2026). Immunotherapy and circulating tumor DNA in HPV-positive oropharyngeal cancer: a systematic review and exploratory meta-analysis of survival and surveillance outcomes. Cancer Treatment and Research Communications, 49, 101477. https://doi.org/10.1016/j.ctarc.2026.101477
Vancouver
Aouf MM, Tamás L, El-Shirbeny HA, Abdel-Maboud M, Dános K. Immunotherapy and circulating tumor DNA in HPV-positive oropharyngeal cancer: a systematic review and exploratory meta-analysis of survival and surveillance outcomes. Cancer Treatment and Research Communications. 2026;49:101477. doi:10.1016/j.ctarc.2026.101477
BibTeX
@article{Aouf2026,
author = {Aouf, Mohammad Mahmoud and Tamás, László and El-Shirbeny, Hussein A and Abdel-Maboud, Mohamed and Dános, Kornél},
title = {Immunotherapy and circulating tumor DNA in HPV-positive oropharyngeal cancer: a systematic review and exploratory meta-analysis of survival and surveillance outcomes},
journal = {Cancer Treatment and Research Communications},
year = {2026},
volume = {49},
pages = {101477},
doi = {10.1016/j.ctarc.2026.101477}
}
EUVIMED